Dr. Shai Shimony
Principal Investigator
Boston, Massachusetts, United States
AML Research
Biography
Dr. Shai Shimony is a physician at Dana-Farber Cancer Institute specializing in acute myeloid leukemia (AML) treatment and research. His work focuses on advancing diagnosis, risk-stratification, and management strategies for AML patients.
Dr. Shimony's research contributes to the comprehensive understanding of AML, including the integration of minimal residual disease (MRD) monitoring into therapeutic decision-making and the application of newly approved therapeutic agents to improve patient outcomes.
Official Profile
Learn more about Dr. Shai Shimony's clinical practice and research at Dana-Farber Cancer Institute:
View official profile at Dana-Farber Cancer InstituteResearch Contributions
Research Impact
Dr. Shai Shimony has authored 58+ peer-reviewed publications contributing to advances in leukemia treatment. Their research has been published in leading medical journals and presented at major national and international conferences.
Explore Additional Research
Find additional publications and research by Dr. Shai Shimony:
Search PubMed for publications by Dr. Shai ShimonyCurrent Research Projects
AML Active
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.
Principal Investigator: Dr. Shai Shimony
Institution: Dana-Farber Cancer Institute
Location
Boston, Massachusetts
Timeline
Start: January 2024
Completion: December 2027